2. Signaling Pathways
  3. Anti-infection
  4. HBV

HBV

Hepatitis B virus

HBV

Related Products

PDF 0.42 MB

HBV (Hepatitis B virus), abbreviated HBV, is a species of the genus Orthohepadnavirus, which is likewise a part of the Hepadnaviridae family of viruses. HBV causes the disease hepatitis B. The hepatitis B virus is classified as the type species of the Orthohepadnavirus, which contains three other species: the Ground squirrel hepatitis virus, Woodchuck hepatitis virus, and theWoolly monkey hepatitis B virus. The genus is classified as part of the Hepadnaviridae family. HBV is divided into four major serotypes (adr, adw, ayr, ayw) based on antigenic epitopes present on its envelope proteins, and into eight genotypes (A–H) according to overall nucleotide sequence variation of the genome. The genotypes have a distinct geographical distribution and are used in tracing the evolution and transmission of the virus. Differences between genotypes affect the disease severity, course and likelihood of complications, and response to treatment and possibly vaccination.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N10404
    Junceellolide C
    		Inhibitor
    Junceellolide C is a transcription inhibitor of cccDNA. Junceellolide C inhibits HBV DNA replication and significantly decreases the level of supernatant HBV RNA with EC50 values of 5.19, 3.52 μM respectively in HepAD38 cells. Junceellolide C is a potent anti-HBV agent.
    Junceellolide C
  • HY-148782
    HBV-IN-31
    		Inhibitor
    HBV-IN-31 is a potent cccDNA (covalently closed circular DNA) inhibitor. HBV-IN-31 shows anti-HBV activity with an IC50 value of 0.13 µM for HBsAg. HBV-IN-31 inhibits cell growth.
    HBV-IN-31
  • HY-123767
    HEC72702
    		Inhibitor
    HEC72702 is a potent and orally active hepatitis B virus capsid inhibitor with an EC50 values of 0.039 µM. HEC72702 dose-dependently reduced HBV DNA in both the plasma and livers.
    HEC72702
  • HY-114956
    AT-61
    		Inhibitor
    AT-61 is a non nucleoside HBV replication inhibitor. AT-61 prevents the capsid formation of pre genomic RNA, resulting in the production of empty capsids. AT-61 has the activity of drug-resistant mutant strains. AT-61 can be used for research on hepatitis B virus infection.
    AT-61
  • HY-177667B
    Tomligisiran sodium scrambled negative control
    		Inhibitor
    Tomligisiran sodium scrambled negative control is the sequence scrambled negative control of Tomligisiran sodium.
    Tomligisiran sodium scrambled negative control
  • HY-145638
    Xalnesiran
    		Inhibitor
    Xalnesiran (RO7445482) is a small interfering RNA molecule that targets a conserved region of the
    hepatitis B virus (HBV) genome. Xalnesiran can be used for the research of chronic hepatitis B infection.
    Xalnesiran
  • HY-W754691
    Glaziovine
    		Inhibitor
    Glaziovine is an antiviral agent found in Hypserpa nitida. Glaziovine exhibits significant inhibitory activity against HBV, capable of suppressing hepatitis B virus surface antigen (HBsAg) secretion in Hep G2.2.15 cells transfected with HBV, with an IC50 of 8 nM.
    Glaziovine
  • HY-144047
    HBV-IN-16
    		Inhibitor
    HBV-IN-16 is a potent inhibitor of covalently closed circular DNA (cccDNA). cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-16 is a quinoline derivative. HBV-IN-16 has the potential for the research of HBV infection (extracted from patent WO2019121357A1, compound 1).
    HBV-IN-16
  • HY-146011
    HBV-IN-21
    		Inhibitor
    HBV-IN-21 (Compound II-8b) is an HBV DNA replication inhibitor with an IC50 of 2.2 µM. HBV-IN-21 can interact HBV 4 capsid protein with good affinity (KD = 60.0 μM).
    HBV-IN-21
  • HY-144322
    HBV-IN-18
    		Modulator
    HBV-IN-18 (Compound 3) is an HBV capsid assembly modulator (CpAM) with an EC50 of 2790 nM.
    HBV-IN-18
  • HY-B0017S
    Telbivudine-d4
    		Inhibitor
    Telbivudine-d4 is deuterium labeled Telbivudine. Telbivudine (Epavudine), an orally active thymidine nucleoside analog, is a potent antiviral inhibitor of hepatitis B virus (HBV) replication.
    Telbivudine-d<sub>4</sub>
  • HY-177667A
    Tomligisiran sodium
    		Inhibitor
    Tomligisiran sodium is a siRNA in JNJ-3989 (JNJ-73763989). JNJ-3989 is comprised of 2 siRNAs (Daplusiran and Tomligisiran), that target hepatitis B virus (HBV) mRNAs for degradation, thereby inhibiting HBV replication.
    Tomligisiran sodium
  • HY-W676876
    Oxynitidine
    		Inhibitor
    Oxynitidine is an HBV inhibitor (ID50=30.8 µg/mL), which can effectively inhibit the DNA replication activity of HBV. Oxynitidine can be used in the study of viral infections.
    Oxynitidine
  • HY-P992458
    SBT8230
    		Inhibitor
    SBT8230 is an ASGR1-targeted TLR8 agonist and an ASGR1-TLR8 immune TAC conjugate. SBT8230 achieves liver enrichment via conjugation with an anti-ASGR1 antibody, activates myeloid cells and induces anti-HBV immune responses. SBT8230 is applicable to research on chronic hepatitis B infection. The corresponding isotype control is: Human lgG1 kappa,lsotype Control (HY-P99001).
    SBT8230
  • HY-177654B
    Ozisiran sodium scrambled negative control
    		Inhibitor
    Ozisiran sodium scrambled negative control is the sequence scrambled negative control of Ozisiran sodium.
    Ozisiran sodium scrambled negative control
  • HY-163580
    HBV/HDV-IN-3
    		Inhibitor
    HBV/HDV-IN-3 (Compd 1) is a dual HBV and HDV inhibitor, with an EC50 of <50 nM against HBV.
    HBV/HDV-IN-3
  • HY-10545
    Taribavirin
    		Inhibitor
    Taribavirin is an orally active inosine monophosphate dehydrogenase inhibitor, has activity against a wide range of viruses, especially the hepatitis C virus and influenza virus. Taribavirin, is a ribavirin proagent, is designed to concentrate within the liver to target HCV-infected hepatocytes while minimizing distribution within red blood cells (RBCs) and the development of hemolytic anemia.
    Taribavirin
  • HY-155547
    HBV-IN-34
    		Inhibitor
    HBV-IN-34 (compound 17i) is a potent HBsAg production inhibitor. HBV-IN-34 exhibits excellent in vitro anti-HBV potency, with an EC50 of 0.018 μM and 0.044 μM for HBV DNA and HBsAg, respectively.
    HBV-IN-34
  • HY-N11792
    Pedunculosumoside F
    		Control
    Pedunculosumoside F is a homoflavonoid glucoside. Pedunculosumoside F can be isolated from Ophioglossum pedunculosum. Pedunculosumoside F has cytotoxicity against HepG2 22.15 cells with CC50 value of 56.7 μM without anti-HBV activity. While its analogs block HBsAg secretion in HBV-infected HepG2 2.2.15 cells.
    Pedunculosumoside F
  • HY-165485
    OSL-95II
    		Inhibitor
    OSL-95II is an antiviral agent. OSL-95II is a potent BVDV and WNV inhibitor. OSL-95II is a better inhibitor of HBV than SP169. OSL-95II inhibits dengue virus production.
    OSL-95II
Cat. No. Product Name / Synonyms Application Reactivity